Stockreport

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium, Inc.  (EQ) 
Last equillium, inc. earnings: 3/26 04:07 pm Check Earnings Report
PDF Treatment with itolizumab did not improve complete or overall response rates at Day 29Itolizumab achieved statistical significance in multiple secondary endpoints demons [Read more]